The cancer gene MYC drives unrestrained growth of most human cancers. It has been called the “Mount Everest” of cancer research because of the difficulty of designing medications that can disable it, and the expectation that an effective MYC drug could help so many cancer patients. Research groups from the The Wertheim UF Scripps Institute in Florida, the Max Planck Institute of Molecular Physiology in Dortmund and the University of Münster have joined forces and climbed that peak by developing Nature-inspired compounds chopping up MYC’s RNA. This innovative RNA degrader approach could also open new routes to summit other similarly hard-to-treat diseases.